Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2003
12/10/2003CN1460471A Fenofibrate soft capsule and its preparation method
12/10/2003CN1130361C Process for producing isooxazolidinedione compound
12/10/2003CN1130349C H3 receptor liqands of phenyl-alkyl-imidazoles type
12/09/2003US6660891 Methods for the production of D-chiro-inositol and the use of D-chiro inositol obtained therefrom
12/09/2003US6660879 Use of the compound in clinical conditions associated with insulin resistance.
12/09/2003US6660859 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases
12/09/2003US6660843 Fusion of Fc domains with biologically active peptides
12/09/2003US6660777 Comprehensive pharmacologic therapy for treatment of obesity
12/09/2003US6660763 Bis-indolylquinone compounds
12/09/2003US6660760 Heterocyclic aromatic compounds useful as growth hormone secretagogues
12/09/2003US6660752 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
12/09/2003US6660748 1-azabicyclo(2.2.1)heptane or quinuclidine derivatives; treating or preventing neuronal damage associated with neurological diseases
12/09/2003US6660746 Cardiovascular disorders
12/09/2003US6660744 Pyrazolopyrimidines as therapeutic agents
12/09/2003US6660740 Sorbitol dehydrogenase inhibitors
12/09/2003US6660738 Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction
12/09/2003US6660732 Ureas and thioureas inhibit production of cytokines
12/09/2003US6660728 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
12/09/2003US6660300 Antidiabetic metformin HCl salt; high water solubility and a limited window of absorption; hydrophilic and hydrophobic polymers
12/09/2003US6660297 Nutritional supplement to treat macular degeneration
12/09/2003CA2306103C Novel once-a-day controlled release sulfonylurea formulation
12/09/2003CA2227298C Paroxetine controlled release compositions
12/09/2003CA2202075C Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
12/09/2003CA2140247C Novel vitamin d analogues
12/09/2003CA2106967C Thiazolidinedione derivatives, production and use thereof
12/04/2003WO2003100438A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003WO2003099874A1 Extraction of unmilled psyllium
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099836A1 C-aryl glucoside sglt2 inhibitors and method
12/04/2003WO2003099827A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003WO2003099821A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
12/04/2003WO2003099820A1 Pyrazolo-pyrimidine aniline compounds
12/04/2003WO2003099819A2 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
12/04/2003WO2003099818A1 Substituted quinazolinone compounds
12/04/2003WO2003099811A1 Kinase inhibitors
12/04/2003WO2003099808A1 Substituted heterocyclic compounds and methods of use
12/04/2003WO2003099805A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003WO2003099792A1 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
12/04/2003WO2003099786A2 Aromatic sulfones and their medical use
12/04/2003WO2003099783A2 Tropane compounds
12/04/2003WO2003099781A2 METHODS FOR THE IDENTIFICATION OF IKKα FUNCTION AND OTHER GENES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
12/04/2003WO2003099776A1 Calcium receptor modulating arylalkylamines
12/04/2003WO2003099775A1 Sulfone liver x-receptor modulators
12/04/2003WO2003099773A1 Ccr9 inhibitors and methods of use thereof
12/04/2003WO2003099772A1 Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof
12/04/2003WO2003099769A1 Anilino liver x-receptor modulators
12/04/2003WO2003099766A1 (2s)-2-ethylphenylpropionic acid derivative
12/04/2003WO2003099765A1 β-ALANINE DERIVATIVE AND USE THEREOF
12/04/2003WO2003099763A1 N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors
12/04/2003WO2003099759A1 Preparation and application of transhintotalphenolic acid
12/04/2003WO2003099337A2 Inclusion complexes of rosiglitazone
12/04/2003WO2003099335A1 Potassium alginate as pharmaceutical excipient and compositions thereof
12/04/2003WO2003099332A1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
12/04/2003WO2003099331A1 Insulin resistance improving agents
12/04/2003WO2003099318A2 Pancreas-specific proteins
12/04/2003WO2003099315A1 A pharmaceutical composition comprising a retro-iverso isomer peptide
12/04/2003WO2003099314A1 Novel exendin agonist formulations and methods of administration thereof
12/04/2003WO2003099311A1 Chewable compositions containing a gel-forming extract of psyllium
12/04/2003WO2003099289A2 Compositions and their uses for alleviating pain
12/04/2003WO2003099281A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
12/04/2003WO2003099279A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003WO2003099256A2 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES)
12/04/2003WO2003099215A2 Antisense modulation of glucocorticoid receptor expression
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099194A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003075977A3 Agglomerated particles for aerosol drug delivery
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003074485A3 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063846A3 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003060096A3 Assay for the detection of factors that modulate the expression of ingap
12/04/2003WO2003059875A3 DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
12/04/2003WO2003057380A3 Compositions including ammonia oxidizing bacteria and methods of using same
12/04/2003WO2003057170A3 Oral insulin therapy
12/04/2003WO2003050281A3 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity
12/04/2003WO2003049692A3 The use of acyl salicylates as heat shock inducers
12/04/2003WO2003043581A3 Composition and method for modulating bar/fxr receptor activity
12/04/2003WO2003030878A3 Galenic microparticulate oral formulation
12/04/2003WO2003030867A3 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid
12/04/2003WO2003028736A3 Pharmaceutical preparations comprising alkyl phosphocholine compounds in liposomes which may be sterile-filtered or heat-sterilised
12/04/2003WO2003024946A3 Oxamate derivatives containing a variously substituted nitrogen heterocycle
12/04/2003WO2003014145A3 Peptides that bind to atherosclerotic lesions
12/04/2003WO2003011225A3 Calcium glutarate supplement and phosphorus binder
12/04/2003WO2003006996A3 Natural ligand of gpcr chemr23 and uses thereof
12/04/2003WO2002102310A3 Proteins associated with cell growth, differentiation, and death
12/04/2003WO2002068635A3 Methods of inhibiting expression of a target gene in mammalian cells
12/04/2003WO2002064827A3 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof
12/04/2003WO2002057427A3 Mammalian tumor susceptibility gene products and their uses
12/04/2003WO2001072771A3 Insulin and igf-1 receptor agonists and antagonists
12/04/2003US20030225286 2-((3-Cyclohexyl-2-(2,5-dioxo-4-(thiophen-2-yl)methylimida-zol idin-1-yl)propanoyl)amino) thiazole-4-carboxylic acid methyl ester, e.g.; antidiabetic agents; hypoglycemic agents; a glucose sensor in beta-cells and hepatocytes
12/04/2003US20030225283 2-Substituted phenyl,3-polar ring,N-heroaromatic propion-amides, e.g., 1-(2-(3,4-Dichlorophenyl)-3-(tetrahydro-furan-2-yl)-propionyl)-3- methylurea; antidiabetic agents; increase the flux of glucose metabolism in beta-cells and hepatocytes
12/04/2003US20030225273 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
1 ... 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 ... 1298